Introduction
============

Neural stem cells (NSCs), one of somatic stem cell types, can differentiate into various types of neurons and glial cells of the central nervous system (CNS) in response to distinct signaling cues ([@ref1]) and their transplantation could reverse the pathophysiology of CNS disorders in animal models ([@ref2]). Thus, NSCs have long been considered as a highly suitable cell source for restoring damaged nerve tissues in various neurodegenerative diseases ([@ref3], [@ref4]). Despite the clinical potentials of the brain tissue-derived NSCs, their limited accessibility and the potential risk of immune rejection upon allogeneic transplantation may preclude their clinical application. Recent induced pluripotent stem cell (iPSC) technology ([@ref5]) open a new avenue of patient-specific clinical applications such as cell replacement therapy. Since iPSCs are equivalent to embryonic stem cells (ESCs) in their self-renewal capacity as well as their pluripotency, they have been considered as an alternative cell source for transplantable patient-specific NSCs. However, there are also some roadblocks of iPSC-based cell therapy such as the potential risk of tumor formation upon transplantation due to the residual undifferentiated pluripotent stem cells even after long differentiation steps.

Alternatively, ectopic expression of cell type--specific genes could lead a direct cell fate transition from a somatic cell state into completely distinct cellular identities without first generating iPSCs ([@ref6]-[@ref12]). This direct conversion technology could also be a useful tool to generate patient-specific NSCs which are non-tumorigenic ([@ref10], [@ref13], [@ref14]). Some previous studies have used the forced expression of the Yamanaka's reprogramming factors, *OCT4*, *SOX2*, *KLF4*, and *C-MYC* (OSKM), to convert somatic cells into human induced neural stem cells (hiNSCs) with a combined treatment of small molecules which can facilitate the reprogramming procedure ([@ref15], [@ref16]). However, the iNSC conversion process using OSKM could involve a transiently acquired pluripotent state, suggesting the potential risk of tumor formation using this reprogramming strategy ([@ref17]). In other cases of hiNSC generation, reprogramming could be achieved by overexpression of a single transcription factor ([@ref18]-[@ref20]) or a combination of cell type-specific genes ([@ref21]). Those directly reprogrammed hiNSCs are non-tumorigenic upon transplantation to the animal model ([@ref18]-[@ref20]). Nevertheless, the extremely low efficiency as well as unclear reproducibility of iNSC generation have been remained as a major roadblock of hiNSC technology ([@ref15], [@ref19], [@ref21], [@ref22]).

Previously we have also described the generation of iNSCs from mouse fibroblasts through the ectopic expression of NSC-specific transcription factors, *Brn4*, *Sox2*, *Klf4*, and *c-Myc* (BSKM) ([@ref10], [@ref11]). The directly converted iNSCs are nearly indistinguishable from the brain tissue-derived NSCs in their morphology, gene expression patterns, epigenetic status, self-renewal capacity, and both *in vitro* and *in vivo* multipotency ([@ref10], [@ref11], [@ref14], [@ref23]). Moreover, iNSC could ameliorate the disease phenotypes upon transplantation into animal models without forming tumor, showing their therapeutic potentials for CNS diseases ([@ref14], [@ref24]). More importantly, we recently demonstrated that the BSKM-mediated iNSC generation is a direct process that does not involve an intermediate pluripotent state ([@ref25]), indicating that BSKM may be a highly reliable and safe reprogramming factor combination for generating transplantable hiNSCs. However, the reprogramming capacity of BSKM in human cells has yet to be determined ([@ref26]).

In the current study, we have established an efficient and reproducible method for generating hiNSCs using fibroblasts from multiple origins by introducing a defined and optimized set of reprogramming factors, resulting in a robust hiNSC conversion within 7 days of transduction. The transdifferentiated hiNSCs exhibited typical features of NSCs such as morphology, gene expression patterns, and differentiation capacity. Our robust and reproducible reprogramming strategy for hiNSC generation may facilitates hiNSC-based clinical translation.

Materials and Methods
=====================

Cell culture
------------

Human fibroblasts maintained in DMEM with high glucose (Welgene) containing 10% fetal bovine serum (Seradigm), 1× MEM/NEAA (Gibco), and 1× penicillin/streptomycin/glutamine (Gibco). The ESC-derived NSCs were maintained in DMEM/F12 (Corning) supplemented with 100× N2 supplement (Gibco), 50× B27 without vitamin A (Gibco), 1% penicillin/streptomycin (PS) (Gibco), 1% GlutaMAX (Gibco), 55 *μ*M *β*-mercaptoethanol (Gibco), 0.05% Bovine serum albumin fraction V (Invitrogen), 10 ng/ml leukemia inhibitory factor, 3 *μ*M CHIR99021 (Tocris), and 2 *μ*M SB431542 (Sigma). hiNSCs were generated and maintained in neural stem cell expansion medium (NSCEM), composed of ReNcell NSC Maintenance Medium (Merck) supplemented with 20 ng/ml bFGF (Peprotech), 20 ng/ml EGF (Peprotech), 0.5 *μ*M phorbol-12-myristate-13-acetate (Sigma), 3 *μ*M CHIR99021 (Tocris), and 2 *μ*M SB431542 (Sigma). The H9 hESCs were maintained in TeSR^TM^-E8^TM^ medium (STEMCELL Technologies) and subcultured using the ReLeSR^TM^ (STEMCELL Technologies) according to the manufacturer's instructions. Differentiation of hESC into NSCs was performed as previously described ([@ref27]). Briefly, hESCs were detached by ReleSR^TM^ (STEMCELL Technologies) to form the Embryoid bodies (EBs) and EBs were cultured in the neural induction medium (NIM) containing DMEM/F12 (Corning) supplemented with 1x N2 (Gibco), 1× B27 without vitamin A (Gibco), 1% penicillin/streptomycin (Gibco), 1% GlutaMAX^TM^ (Gibco), 1% NEAA (Gibco), 55 *μ*M *β*-mercaptoethanol (Gibco) in the presence of 3 *μ*M CHIR99021, 2 *μ*M SB431542 and 10 ng/ml hLIF (Millipore). After 7 days, the EBs were dissociated into single cells using TrypLE^TM^ (Gibco) and re-plated on the Matrigel (Corning)-coated surfaces. The hESC-derived NSCs were stabilized in NIM by serial passaging.

Retrovirus production
---------------------

Retroviral particles were produced by transfection of pMX vectors encoding reprogramming factors (10 *μ*g) into Platinum E cells (Cell Biolabs) using 30 *μ*l of jetPEI transfection reagent (Polyplus). After 48 hrs, the supernatants containing viral particles were carefully collected and filtered through a 0.22-*μ*m syringe filter (Minisart).

Generation of hiNSCs
--------------------

To generate hiNSCs, 5×10^4^ human fibroblasts were plated onto a gelatin-coated 35 mm dish. Next day, fibroblasts were transduced with retroviral particles encoding a reprogramming factor combination using 6 *μ*g/ml protamine sulfate (Sigma), re-plated onto a Matrigel (Corning)-coated 35 mm dish and cultured in NSCEM, which was replaced with fresh medium every other day. Once the initial colonies were observed, stable hiNSC lines were established by serial passaging. For the comparative analysis of reprogramming potentials of distinct factor combinations in hiNSC generation, we used the identical conditions from previous studies for each reprogramming cocktails, OSKM ([@ref15]), *OCT4* ([@ref19]), *SOX2* ([@ref18]), and *SOX2*＋*HMGA2* ([@ref21]).

Gene expression analysis
------------------------

Total RNA was isolated by using a Hybrid-RTM RNA isolation kit (GeneAll) according to the manufacturer's protocol. RNA (1 *μ*g) was converted to cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR was performed using GoTag Green Master Mix (Promega). qPCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) on a QuantStudio 3 Real-Time PCR instrument (Applied Biosystems). ΔCt values were calculated by subtracting the *GAPDH* Ct value from that of each target gene. Relative expression levels were calculated by using the 2^−ΔΔCt^ method. The primer sets are listed in [Supplementary Table S1](#S1){ref-type="supplementary-material"}.

RNA sequencing analysis
-----------------------

Quality of the RNA-seq raw reads were assessed with Fastqc (0.11.8) and the reads were aligned with STAR (v2.6.1a) on UCSC hg38 human genome. Gene expression level was calculated and normalized with Cuffnorm (v2.2.1, Cufflinks). Genes with more than two-fold difference of expression levels between hFFs and hESC-derived NSCs and FPKM value of more than 2 were chosen to generate the heatmap. Selected genes were sorted to be clustered into different groups of up-regulated or down-regulated genes compared to hESC-derived NSCs. Data visualization was conducted with heatmap.2 function of R package gplots (v3.0.1.1).

Immunocytochemistry
-------------------

Cells were fixed with 4% paraformaldehyde (Chemcruz) for 15 min at room temperature, and then washed three times with PBS (Life Genomics). After washing, the fixed cells were permeabilized and blocked with PBS containing 0.03% Triton X-100 (Sigma) and 6% BSA (Sigma) for 1 hr at room temperature. The following primary antibodies were used: goat anti-*SOX2* (Santa Cruz, 1：200), goat anti *BRN2* (Santa Cruz, 1：200), rabbit anti-*BLBP* (Santa Cruz, 1：200), rat anti-*MSI1* (MBL, 1：200), rabbit anti-*MSI2* (Abcam, 1：200), mouse anti-*TUJ1* (Covance, 1：500), rabbit anti-*GFAP* (Dako, 1：500), mouse anti-*MBP* (Abcam, 1：500), rabbit anti-*GABA* (Sigma, 1：200), rabbit anti-*GLU* (Sigma, 1：200), goat-anti *ChAT* (Merck, 1：200), and rabbit anti-*TH* (Merck, 1：200)，and rabbit anti-*MBP* (Abcam, 1：200). Permeabilized cells were incubated with primary antibodies for 16 hrs at 4℃, washed three times with PBS, and incubated with secondary antibodies for 2 hrs at room temperature. Counterstaining was performed with Hoechst 33342 (Sigma).

*In vitro* differentiation of NSCs
----------------------------------

To differentiate hiNSCs and hESC-derived NSCs into neurons, the cells were dissociated into single cells and 1×10^4^ cells were plated onto Matrigel-coated single well of 4-well plate. After 24 hrs, the medium was replaced with a 1：1 mix of DMEM/F12 (Corning) and Neurobasal Medium (Gibco) supplemented with 100× N2 supplement (Gibco), 50× B27 (Gibco), 1% PS (Gibco), 1% GlutaMAX (Gibco), 1% NEAA (Gibco), 55 *μ*M *β*-mercaptoethanol (Gibco), 1 *μ*g/ml heparin (Sigma), 10 ng/ml BDNF (Peprotech), 10 ng/ml GDNF (Peprotech), 200 *μ*M ascorbic acid (Peprotech), and 125 *μ*M cAMP (Peprotech). To differentiate hiNSCs and hESC-derived NSCs into astrocytes, the cells were dissociated and plated as above. After 24 hrs, the medium was replaced with DMEM/F12 (Corning) supplemented with 100× N2 supplement (Gibco), 50× B27 (Gibco), 1% PS (Gibco), 1% GlutaMAX (Gibco), 1% NEAA (Gibco), 10 ng/ml BMP4 (Peprotech), and 20 ng/ml CNTF (Peprotech). Two weeks after inducing differentiation, the neurons and astrocytes were immunostained with antibody against TUJ1 and GFAP, respectively. The subtypes of neurons were determined at 5 weeks after inducing differentiation.

Statistical analysis
--------------------

All information related to statistical tests is documented in the corresponding figure legends and in the supplementary figure legends. Data are reported as mean values from at least three replicates, with error bars denoting SD. Statistical significance was evaluated with unpaired two-tailed Student's t-test.

Results
=======

Robust and reproducible generation of hiNSCs
--------------------------------------------

During the early phase of reprogramming, an enhanced proliferation rate of somatic cells has been shown to be critical for achieving improved reprogramming efficiency ([@ref28], [@ref29]). This prompted us to hypothesize that the addition of NSC-specific mitogens which can activate cell cycle may elevate the direct conversion efficiency toward NSCs. To this end, the human fetal fibroblasts (hFFs) transduced with BSKM ([@ref10], [@ref11]) were cultured in neural stem cell expansion medium (NSCEM) supplemented with EGF and bFGF and three additional small molecules; phorbol-12-myristate-13-acetate, CHIR99021, and SB431542, which are all known to activate a mitotic pathway in early-stage progenitors of the neuroectoderm ([@ref30], [@ref31]) ([Fig. 1A](#F1){ref-type="fig"}). However, BSKM-transduced hFFs did not show any morphological changes until 4 weeks after viral infection. Most of the transduced hFFs maintained their typical fibroblast morphology with a slow proliferation rate and eventually underwent cellular senescence (data not shown). This finding suggests that BSKM is not sufficient to convert human fibroblasts into an NSC-like state.

Previous studies declaimed that the forced expression of *SV40 large T antigen* (*SV40LT*) significantly enhances the reprogramming efficiency of human iPSCs by improving cell proliferation rates and also by reducing cellular apoptosis ([@ref32]). Additional *SV40LT* could also facilitate the transdifferentiation and expansion of human induced hepatocytes ([@ref12]). Thus, to improve the conversion efficiency of hiNSCs, we introduced the *SV40LT* into hFFs together with BSKM ([Fig. 1A](#F1){ref-type="fig"}). After 7 days of viral infection, we found the initial iNSC clusters with typical epithelial morphology and higher proliferation capacity compared with those of unreprogrammed hFFs (12.25±9.56 colonies per individual experimental group) ([Fig. 1A](#F1){ref-type="fig"}). At 2 weeks of transduction, a NSC-like cell population with homogenous morphology were observed and they could be stably expanded along the serial passaging ([Fig. 1B and 1C](#F1){ref-type="fig"}). A subset of NSC markers started to be expressed in established hiNSCs (passage 1) with complete suppression of hFF markers and became strongly activated upon further passaging (passage 10) ([Fig. 1D](#F1){ref-type="fig"}), indicating the gradual reprogramming process of hiNSCs as in mouse case ([@ref10], [@ref11]). Similarly, hiNSCs generated with BSKM and *SV40LT* exhibited the gradual morphological changes during further passaging, i.e., less defined shapes in early passage and well-defined and typical NSC-like shapes at later passages ([Fig. 1C](#F1){ref-type="fig"}) (hereafter referred to BSKM^LT^ hiNSCs).

Although previous studies demonstrated the direct conversion of human somatic cells into hiNSCs, the reproducibility of previous reprogramming cocktails for generating hiNSCs using human somatic cells from distinct origins has yet to be determined ([@ref18], [@ref20]), strongly suggesting the necessity of highly reproducible method for hiNSCs. Thus, we first tried to evaluate the reproducibility of our reprogramming factor combination (BSKM plus *SV40LT*) in hiNSC generation. For this, we introduced our factor combination into two lines of human fibroblasts, CRL-2097 human dermal fibroblasts (obtained from American Type Culture Collection, Manassas, VA, USA) and F134 human adult fibroblasts ([@ref33]), which are derived from distinct individuals. Similar with hFFs ([Fig. 1C and 1D](#F1){ref-type="fig"}), both CRL-2097 and F134 fibroblasts could be reprogrammed into hiNSCs ([Supplementary Fig. S1A and S1C](#S1){ref-type="supplementary-material"}) expressing multiple NSC markers ([Supplementary Fig. S1B and S1D](#S1){ref-type="supplementary-material"}). Taken together, our data indicate that our reprogramming cocktail is highly robust and reproducible for generating hiNSCs from distinct genetic backgrounds.

BSKM^LT^ hiNSCs displayed the specific morphological characteristics of radial glial cells in the ventricular zone of the developing brain ([Fig. 1C](#F1){ref-type="fig"}). To further assess the regional identity of BSKM^LT^ hiNSCs, we next checked the expression patterns of region-specific maker genes which play critical roles in establishing the precise domain boundaries of the developing nervous system ([@ref34]). Notably, the expression pattern of certain genes such as *PAX6*, *BRN2*, *MSI1*, *PROM1*, and *RC1* varied among the BSKM^LT^ hiNSC lines, although the pan-NSC markers such as *SOX2*, *HEY2*, *MSI2*, *BLBP*, *CXCR4*, and *GLAST* were commonly expressed ([Fig. 1D](#F1){ref-type="fig"}, [Supplementary Fig. S1B and S1D](#S1){ref-type="supplementary-material"}). These data could be explained by the heterogeneity of reprogrammed BSKM^LT^ hiNSCs, which represent distinct regional identities and developmental stages of NSCs. Despite the heterogeneous identity of BSKM^LT^ hiNSCs, all BSKM^LT^ hiNSC lines from distinct origins were negative for *PLZF*, a transcription factor that functions in early neurodevelopment and disappears in the late stage of neurodevelopment ([@ref35]), supporting that BSKM^LT^ hiNSCs more likely represent late-stage radial glial cells in developing brain ([Fig. 1D](#F1){ref-type="fig"}, [Supplementary Fig. S1B and S1D](#S1){ref-type="supplementary-material"}).

Comparative analysis of reprogramming potentials of distinct factor combinations in hiNSC generation
----------------------------------------------------------------------------------------------------

Previous studies claimed that the reprogramming efficiency toward hiNSCs was less than 0.96% and the time required for hiNSC generation was around 20 days (up to 35 days) ([Supplementary Table S2](#S1){ref-type="supplementary-material"}) ([@ref15], [@ref18], [@ref19], [@ref21], [@ref22]). Thus, to develop a highly efficient and reproducible protocol for hiNSC generation, we revisited the reprogramming potentials of previously reported hiNSC reprogramming cocktails by comparing the reprogramming efficiency of distinct factor combinations including ours. For this, we introduced distinct factor combinations, OSKM ([@ref15], [@ref16], [@ref22]), *OCT4* alone ([@ref19], [@ref20]), *SOX2* alone ([@ref18], [@ref20]), *SOX2*＋*HMGA2* ([@ref21]), and BSKM plus *SV40LT*. In addition, to scale down the number of factors required for hiNSC generation, we also introduced the following combinations, *SOX2*＋*KLF4*＋*SV40LT* (SK^LT^), *SOX2*＋*C-MYC*＋*SV40LT* (SM^LT^), and *SOX2*＋*KLF4*＋*C-MYC*＋*SV40LT* (SKM^LT^) ([Fig. 2A](#F2){ref-type="fig"}).

On day 2 post-infection of each combination, 5×10^4^ transduced cells were re-plated onto Matrigel-coated plates and cultured in NSCEM ([Fig. 2A](#F2){ref-type="fig"}). For a fair comparison, the expression levels of each exogenous factors were determined by qPCR on day 5 of transduction. The qPCR analysis showed that each exogenous reprogramming factor was successfully introduced and stably expressed in the transduced hFFs ([Supplementary Fig. S2A](#S1){ref-type="supplementary-material"}). To perform an unbiased comparative analysis of direct conversion efficiency using distinct combinations in a time-course manner, we immunoassayed iNSC colonies using antibodies against NSC-specific proteins (*BLBP* and *MSI1*) and the numbers of *BLBP*^＋^/*MSI1*^＋^ colonies were counted every week for 4 weeks of reprogramming period ([Fig. 2A](#F2){ref-type="fig"}). OSKM, SM^LT^, SKM^LT^, and BSKM^LT^ groups but not others exhibited *BLBP*^＋^/*MSI1*^＋^ colonies with substantial morphological changes after 2 weeks post infection ([Fig. 2B, 2C](#F2){ref-type="fig"} and [Supplementary Fig. S2B](#S1){ref-type="supplementary-material"}). Although we found some *BLBP*^＋^/*MSI1*^＋^ colonies in OSKM-transduced hFFs, the number of *BLBP*^＋^/*MSI1*^＋^ colonies was significantly decreased and nearly no colony remained after 4 weeks ([Fig. 2B and 2D](#F2){ref-type="fig"}), suggesting that OSKM may be insufficient to stably maintain a NSC-like state in the reprogrammed cells in our experimental setting. In contrast, the number of both *BLBP* and *MSI* expressing colonies was dramatically increased in hFFs transduced with SM^LT^, SKM^LT^, and BSKM^LT^ upon further passaging ([Fig. 2B and 2D](#F2){ref-type="fig"}). Surprisingly, we found *BLBP*^＋^/*MSI1*^＋^ colonies from SKM^LT^ transduced hFFS within the first week of transduction ([Fig. 2B](#F2){ref-type="fig"}) and the colony numbers were exponentially increased in the third and fourth weeks of reprogramming ([Fig. 2D](#F2){ref-type="fig"}). This data indicates that *BRN4* withdrawal rather facilitates the direct conversion process toward hiNSCs. Notably, SM^LT^ condition in which both *BRN4* and *KLF4* were omitted also exhibited the rapid conversion into hiNSCs within 7 days of transduction ([Fig. 2B](#F2){ref-type="fig"}), although the colony number was slightly lower compared with those of SKM^LT^ and BSKM^LT^ ([Fig. 2D](#F2){ref-type="fig"}). Taken together, our time-course analysis indicates that both *BRN4* and *KLF4* are not essential for hiNSC generation.

Our time-course immunostaining analysis detects fully reprogrammed hiNSCs expressing both *BLBP* and *MSI1*. Thus, it is likely that we may miss intermediate reprogrammed cells which express *BLBP* and *MSI1* partially or only on mRNA level upon introduction of some reprogramming cocktails which failed to generate *BLBP*^＋^/*MSI1*^＋^ colony. To exclude this possibility, we next performed qPCR analysis to explore the early molecular changes upon the introduction of reprogramming incompetent (OKSM, *OCT4* alone, *SOX2* alone, *SOX2*＋*HMGA2*, and *SV40LT* alone) and competent (SM^LT^, SKM^LT^, and BSKM^LT^) factor combinations. For this, we introduced distinct factor combinations in hFFs and determined the expression levels of endogenous NSC markers including *CXCR4*, *PROM1*, *ASCL1*, and *SOX2* every week (up to 4 weeks). Consistent with our immunostaining data, NSC markers were strongly activated in SM^LT^, SKM^LT^, and BSKM^LT^ transduced hFFs ([Fig. 3](#F3){ref-type="fig"}). On the other hand, other reprogramming incompetent cocktails (OSKM, *OCT4* alone, *SOX2* alone, *SOX2*＋*HMGA2*, and *SV40LT* alone) failed to activate NSC markers even after 4 weeks of transduction ([Fig. 3](#F3){ref-type="fig"}), supporting our immunostaining data ([Fig. 2B and 2D](#F2){ref-type="fig"}). Collectively, our data indicate that our factor combinations (SM^LT^, SKM^LT^, and BSKM^LT^) led robust and reproducible hiNSC generation, and SKM^LT^ combination, the optimized factor combination in this study, exhibited the highest conversion efficiency compared with those of SM^LT^ and BSKM^LT^.

hiNSCs share molecular and functional features with hESC-derived control NSCs
-----------------------------------------------------------------------------

To characterize SKM^LT^ hiNSCs, we generated five hiNSC lines from three independently transduced hFFs with SKM^LT^. All the hiNSC lines displayed typical morphology of NSCs with activation of NSC marker genes ([Supplementary Fig. S3A and S3B](#S1){ref-type="supplementary-material"}). Among them, SKM^LT^ hiNSC line 5 showed the strongest expression of NSC-related genes ([Supplementary Fig. S3B](#S1){ref-type="supplementary-material"}) and thus, we selected this line for the rest of analysis. Similar with hESC-derived NSCs, SKM^LT^ hiNSCs exhibited the expression of NSC markers such as *BRN2*, *BLBP*, *MSI1*, and *MSI2* as evidenced by immunocytochemistry ([Fig. 4A](#F4){ref-type="fig"}) and they also displayed the global gene expression pattern similar with that of hESC-derived NSCs as shown by RNA sequencing analysis ([Fig. 4B](#F4){ref-type="fig"}). We also evaluate the *in vitro* differentiation potential of SKM^LT^ hiNSCs by inducing differentiation into both neurons and glial cells. After two weeks of differentiation, SKM^LT^ hiNSCs could differentiate into both *GFAP*^＋^ astrocytes and *TUJ1*^＋^ neurons ([Fig. 4C and 4D](#F4){ref-type="fig"}). SKM^LT^ hiNSCs also exhibited a rare differentiation into oligodendrocytes ([Supplementary Fig. S4A](#S1){ref-type="supplementary-material"}). Notably, the differentiation efficiency into each lineage was quite similar with those of hESC-derived NSCs ([Fig. 4E and 4F](#F4){ref-type="fig"}), indicating that SKM^LT^ hiNSCs are functionally comparable to hESC-derived NSCs. Finally, we also evaluated the *in vitro* differentiation potentials of hiNSCs into other neuronal subtypes. As a result, we found that SKM^LT^ hiNSCs could differentiate into all major neuronal subtypes, namely GABAergic, glutamatergic, cholinergic, and dopaminergic neurons upon the prolonged culture of neurons derived from SKM^LT^ hiNSCs as evidenced by immunostaining using antibodies against *GABA*, *Glutamate*, *ChAT* (choline acetyltransferase), and *TH* (tyrosine hydroxylase), respectively ([Supplementary Fig. S4B](#S1){ref-type="supplementary-material"}). Altogether, our data indicate that SKM^LT^ hiNSCs share key molecular and functional features with hESC-derived NSCs and they are indeed multipotent.

Discussion
==========

Recent studies have described the generation of hiNSCs or induced neural progenitor cells by introducing defined sets of reprogramming factors ([@ref18], [@ref21]). Ring et al. ([@ref18]) transduced single transcription factor, *SOX2*, into human fetal fibroblasts in the presence of FGF2 and EGF to generate hiNSCs. Yu et al. ([@ref21]) showed that the transduction of an aging-related factor, *HMGA2*, together with *SOX2* could enhance the hiNSC generation even from the senescent cells. On the other hand, it was also shown that the complete or partial sets of Yamanaka's factors that are generally used for iPSC generation could be also employed for generating NSC-like cell ([@ref15], [@ref19], [@ref36]). However, several technical limitations remain to be solved before translating hiNSC technology into the clinic. First, the direct conversion process toward hiNSCs using previous protocols is an extremely inefficient (0.003 to 0.96%) and time-consuming process (up to 35 days) ([Supplementary Table S1](#S1){ref-type="supplementary-material"}) ([@ref15], [@ref18], [@ref19], [@ref21], [@ref22], [@ref36]). Second, Yamanaka factor-mediated iNSC generation step may involve a transient activation of pluripotency network, suggesting the potential tumorigenic nature of Yamanaka factor-mediated hiNSCs ([@ref17]).

In contrast, BSKM^LT^ could efficiently and reproducibly generate hiNSCs from multiple human somatic cell populations with distinct origins. BSKM^LT^ combination showed the much higher reprogramming efficiency compared with previously described factor combinations. Throughout further optimization step, we could generate hiNSCs with either SM^LT^ or SKM^LT^, indicating that both *BRN4* and *KLF4* are not essential for hiNSC generation. Indeed, SKM^LT^ combination exhibited the highest reprogramming efficiency (up to 2.4%, around 80 times higher than OKSM) with accelerated conversion process (within 7 days) ([Fig. 2B and 2D](#F2){ref-type="fig"}). This finding could be also explained by the key role of *BRN4* in neuronal differentiation. *BRN4* induces the differentiation of NSCs into neurons in an insulin-like growth factor-1 (IGF-1)-dependent manner ([@ref37]). This neurogenic role of *BRN4* might decrease the yield of the self-replicative hiNSC population during BSKM^LT^ mediated direct conversion process, also indicating the distinct role of *BRN4* in induction of multipotency between human and mouse ([@ref10], [@ref11], [@ref25]).

Recently, we have described that BSKM-mediated iNSC production in mouse is a direct process which does not involve a transient acquisition of pluripotency ([@ref25]). Thus, in contrast to Yamanaka factor-mediated direct conversion process, our direct conversion strategy is much more reliable and robust in the production of transplantable hiNSCs. However, there are still some hurdles remained for further translating our technology into the clinic. First, the cellular identity of transdifferentiated hiNSCs remains elusive. The unclear regional identity of hiNSCs might be caused by the heterogeneity of the reprogrammed cells ([@ref38]) and thus, further clonal assay ([@ref23]) for clearly addressing the regional identity of hiNSCs is highly required to elaborate cellular identity of hiNSCs for future application. Second, we observed that *SV40LT* is essential for the efficient direct conversion toward hiNSCs, resulting in robust and reproducible hiNSC production. However, *SV40LT* is a well-known oncogene capable of inducing malignant transformation of various cells. Thus, the residual expression of *SV40LT* or integrated viral cassettes encoding *SV40LT* should be fully eliminated in hiNSCs for therapeutic applications. Further efforts for inducing transient expression of *SV40LT* without transgene integration such as an episomal vector system ([@ref7], [@ref23]) and *in vitro* transcribed mRNA are required. Third, insertional mutagenesis caused by the viral vector may lead to the continuous expression of exogenous reprogramming factors and the random gene-breaking in reprogrammed iNSCs, potentially resulting in functional defects ([@ref39]). Therefore, as mentioned above, a safer method should be developed for integration-free gene delivery of exogenous reprograming factors.

Our study describes a novel protocol for robustly and reproducibly generating hiNSCs using a well-defined minimized gene set under specific culture conditions. Thus, this current protocol might be highly suitable for producing patient-specific hiNSCs for cell replacement therapy. Moreover, hiNSCs technology might be also useful for the precise *in vitro* modeling of various neuronal disorders and efficient screening of drug candidates.
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![Generation of hiNSCs from hFFs using BSKM with *SV40LT*. (A) Schematic illustration of the reprogramming procedure for generating hiNSCs. Morphological changes during the reprogramming period are shown. Scale bars, 100 *μ*m. (B) Morphology of hiNSCs after 2 weeks of transduction. Scale bars, 100 *μ*m. (C) Morphology of the established hiNSCs at different passages. Scale bars, 100 *μ*m. (D) Expression pattern of NSC- and fibroblast-specific markers were analyzed by RT-PCR in early and later passages of hiNSCs. *GAPDH* was used as a positive control.](IJSC-13-080-f1){#F1}
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Comparative analysis of reprogramming potentials of distinct factor combinations. (A) The schematic illustration depicting the strategy for comparing the reprogramming efficiency of distinct factor combinations. (B) Time-course immunofluorescence analysis for comparing reprogramming potentials of distinct factor combinations. Scale bars, 100 *μ*m. (C) Morphology of hiNSC clusters at 2 weeks after transduction. Scale bars, 100 *μ*m. (D) The number of *BLBP*^＋^/*MSI1*^＋^ colonies were counted in a time-course manner. Data are presented as mean±SD from six independent experiments. \*p\<0.05, \*p\<0.01, \*\*\*p\<0.001.
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![Expression pattern of NSC-specific markers during hiNSC generation. Expression pattern of NSC markers in hFFs transduced with distinct factor combinations was analyzed by qPCR in a time-course manner. All the values were normalized to those of non-transduced hFFs. Data are presented as mean±SD of triplicate values. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](IJSC-13-080-f3){#F3}
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Characterization of SKM^LT^ hiNSCs. (A) Immunofluorescence images of hESC-derived NSCs and SKM^LT^ hiNSCs using antibodies against *BRN2*, *BLBP*, *MSI1*, and *MSI2*. Scale bars, 100 *μ*m. (B) A heat map representing expression profile of genes with more than two-fold expression level difference between hFFs and hESC-derived NSCs. The color represents z-score for gene expression level in log~2~ scale. Clusters with red and blue bar on the left represent genes with lower and higher expression in hFFs compared to hESC-derived NSCs, respectively. (C, D) Differentiation potential of SKM^LT^ hiNSCs into astrocytes (C) and neurons (D) as determined by immunocytochemistry with antibodies against *GFAP* and *TUJ1*, respectively, Scale bars, 100 *μ*m. (E, F) The efficiency of differentiation into astrocytes (E) and neurons (F) from hESC-derived NSCs and SKM^LT^ hiNSCs was quantified and compared via immunostaining with *GFAP* and *TUJ1*, respectively. Data are presented as mean±SD from eight independent experiments. N.S.: not significant.
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